Table 1.

Characteristics of 234 patients with axSpA according to patient-reported flare status. All percentages are calculated on complete data. Values are n (%) unless otherwise specified.

CharacteristicsAll Patients, n = 234No Flare Reported, n = 59Only Past Flares, n = 58Current Flare, n = 117
Males169 (73.5)41 (70.7)37 (66.1)91 (78.4)
Age, yrs, mean (SD)45.5 (11.8)47.0 (12.8)45.7 (11.7)44.7 (11.5)
Time since AS onset, yrs, mean (SD)21.7 (11.7)23.0 (11.0)23.5 (13.7)20.2 (10.8)
White206 (97.6)50 (98)52 (96.3)104 (98.1)
Education above end of high school141 (61.3)37 (63.8)39 (69.6)65 (56.0)
Paid employment176 (75.5)43 (72.9)46 (80.7)87 (74.4)
History of extraarticular symptoms
Uveitis, psoriasis, and/or IBD116 (51.8)24 (41.4)30 (54.5)62 (55.9)
  Psoriasis37 (17.5)7 (12.7)13 (24.5)17 (16.5)
  Uveitis81 (37.2)16 (28.6)22 (39.3)43 (40.6)
  IBD42 (19)10 (17.2)11 (20.8)21 (19.1)
Family history of AS69 (29.5)21 (35.6)13 (22.4)35 (29.9)
Medication, previous month
  NSAID220 (94.0)53 (89.8)55 (94.8)112 (95.7)
  csDMARD55 (23.5)11 (18.6)18 (31.0)26 (22.2)
  Anti-TNF18 (7.7)9 (15.3)7 (12.1)2 (1.7)
BASDAI, mean (SD)4.4 (2.3)2.4 (1.7)4.0 (1.7)5.6 (2.0)
BASFI, mean (SD)3.4 (2.6)1.7 (1.8)2.9 (2.4)4.6 (2.5)
ASQoL, mean (SD)6.7 (5.5)2.5 (3.2)5.3 (4.5)9.5 (5.3)
PASS, acceptable state135.0 (59.2)51.0 (89.5)46.0 (79.3)38.0 (33.6)
  • axSpA: axial spondyloarthritis; AS: ankylosing spondylitis; IBD: inflammatory bowel disease; NSAID: nonsteroidal antiinflammatory drug; csDMARD: conventional synthetic disease-modifying antirheumatic drug; anti-TNF: antitumor necrosis factor; BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; BASFI: Bath Ankylosing Spondylitis Functional Index; ASQoL: AS Quality of Life; PASS: Patient-Acceptable Symptom State.